TNFRSF8 and T-cell non-Hodgkin lymphoma: In a Phase II study in 34 evaluable patients, BV was effective in the treatment of relapsed and refractory, non-anaplastic, CD30-positive T-cell lymphomas, with an overall response rate (ORR) of 41% [7].